These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36051360)

  • 21. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
    O'Hear C; Rubnitz JE
    Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
    Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
    Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
    Fenwarth L; Fournier E; Cheok M; Boyer T; Gonzales F; Castaigne S; Boissel N; Lambert J; Dombret H; Preudhomme C; Duployez N
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.
    Lamba JK; Pounds S; Cao X; Downing JR; Campana D; Ribeiro RC; Pui CH; Rubnitz JE
    Leukemia; 2009 Feb; 23(2):402-4. PubMed ID: 18615103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
    Pollard JA; Loken M; Gerbing RB; Raimondi SC; Hirsch BA; Aplenc R; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2016 Mar; 34(7):747-55. PubMed ID: 26786921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
    Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
    PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults.
    Goldenson BH; Goodman AM; Ball ED
    Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
    Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
    Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
    Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-CD33 monoclonal antibody drug conjugate--Gemtuzumab ozogamicin (GO)].
    Usui N
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():215-8. PubMed ID: 25831755
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.
    Stanchina M; Pastore A; Devlin S; Famulare C; Stein E; Taylor J
    J Hematol Oncol; 2019 Aug; 12(1):85. PubMed ID: 31439003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
    Molnár I; Powell BL
    Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
    Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
    Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia.
    Loke J; Khan JN; Wilson JS; Craddock C; Wheatley K
    Ann Hematol; 2015 Mar; 94(3):361-73. PubMed ID: 25284166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.